Advances of peptides in cancer treatment

Abstract

Zhang Ziqiang, Yang Xiaofeng, Liu Jiehao. Advances of peptides in cancer treatment[J]. Journal of International Oncology, 2015, 42(1): 52-55.

［1］ Meng L, Yang L, Zhao X, et al. Targeted delivery of chemotherapy agents using a liver cancerspecific aptamer［J］. PLoS One, 2012, 7(4): e33434. ［2］ Zhang XX, Eden HS, Chen X. Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates［J］. J Control Release, 2012, 159(1): 2-13. ［3］ Nicolas G, Giovacchini G, MüllerBrand J, et al. Targeted radiotherapy with radiolabeled somatostatin analogs［J］. Endocrinol Metab Clin North Am, 2011, 40(1): 187-204. ［4］ Putzer D, Gabriel M, Henninger B, et al. Bone metastases in patients with neuroendocrine tumor: 68GaDOTATyr3octreotide PET in comparison to CT and bone scintigraphy［J］. J Nucl Med, 2009, 50(8): 1214-1221. ［5］ Bison SM, Konijnenberg MW, Melis M, et al. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments［J］. Clin Transl Imaging, 2014, 2: 55-66. ［6］ Zaccaro L, Del Gatto A, Pedone C, et al. Peptides for tumour therapy and diagnosis: current status and future directions［J］. Curr Med Chem, 2009, 16(7): 780-795. ［7］ Yan Y, Chen K, Yang M, et al. A new 18Flabeled BBNRGD peptide heterodimer with a symmetric linker for prostate cancer imaging［J］. Amino Acids, 2011, 41(2): 439-447. ［8］ Tweedle MF. Peptidetargeted diagnostics and radiotherapeutics［J］. Acc Chem Res, 2009, 42(7): 958-968. ［9］ Wild D, Fani M, Behe M, et al. First clinical evidence that imaging with somatostatin receptor antagonists is feasible［J］. J Nucl Med, 2011, 52(9): 1412-1417. ［10］ Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV16 oncoproteins for vulvar intraepithelial neoplasia［J］. N Engl J Med, 2009, 361(19): 1838-1847. ［11］ Bolonaki I, Kotsakis A, Papadimitraki E, et al. Vaccination of patients with advanced nonsmallcell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide［J］. J Clin Oncol, 2007, 25(19): 2727-2734. ［12］ Bedke J, Stenzl A. IMA901: a peptide vaccine in renal cell carcinoma［J］. Expert Opin Investig Drugs, 2013, 22(10): 13291336. ［13］ Zhang Z, Chen X, Chang X, et al. Vaccination with embryonic stem cells generates effective antitumor immunity against ovarian cancer［J］. Int J Mol Med, 2013, 31(1): 147-153. ［14］ Wiedermann U, Davis AB, Zielinski CC. Vaccination for the prevention and treatment of breast cancer with special focus on Her2/neu peptide vaccines［J］. Breast Cancer Res Treat, 2013, 138(1): 1-12. ［15］ Kimura T, McKolanis JR, Dzubinski LA, et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study［J］. Cancer Prev Res (Phila), 2013, 6(1): 18-26. ［16］ Kelly RJ, Giaccone G. Lung cancer vaccines［J］. Cancer J, 2011, 17(5): 302-308. ［17］ Okuno K, Sugiura F, Itoh K, et al. Recent advances in active specific cancer vaccine treatment for colorectal cancer［J］. Curr Pharm Biotechnol, 2012, 13(8): 1439-1445. ［18］ Weber JS, Vogelzang NJ, Ernstoff MS, et al. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostatespecific membrane antigen in patients with advanced solid tumors［J］. J Immunother, 2011, 34(7): 556-567. ［19］ Akhtar NH, Pail O, Saran A, et al. Prostatespecific membrane antigenbased therapeutics［J］. Adv Urol, 2012, 2012: 973820. ［20］ Toubaji A, Achtar M, Provenzano M, et al. Pilot study of mutant ras peptidebased vaccine as an adjuvant treatment in pancreatic and colorectal cancers［J］. Cancer Immunol Immunother, 2008, 57(9): 1413-1420. ［21］ Markowicz S, Nowecki ZI, Rutkowski P, et al. Adjuvant vaccination with melanoma antigenpulsed dendritic cells in stage Ⅲ melanoma patients［J］. Med Oncol, 2012, 29(4): 2966-2977. ［22］ Chen K, Chen X. Integrin targeted delivery of chemotherapeutics［J］. Theranostics, 2011, 1: 189-200. ［23］ Schally AV, Engel JB, Emons G, et al. Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors［J］. Curr Drug Deliv, 2011, 8(1): 1125. ［24］ Laakkonen P, Vuorinen K. Homing peptides as targeted delivery vehicles［J］. Integr Biol (Camb), 2010, 2(7-8): 326-337. ［25］ Li ZJ, Cho CH. Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery［J］. J Transl Med, 2012, 10 Suppl 1: S1. ［26］ Sotomayor S, MunozMoreno L, Carmena MJ, et al. Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN215) and a bombesin antagonist (RC3095) ［J］. Int J Cancer, 2010, 127(8): 1813-1822. ［27］ Rosca EV, Koskimaki JE, Rivera CG, et al. Antiangiogenic peptides for cancer therapeutics［J］. Curr Pharm Biotechnol, 2011, 12(8): 1101-1116. ［28］ Cardinale D, Guaitoli G, Tondi D, et al. Proteinprotein interfacebinding peptides inhibit the cancer therapy target human thymidylate synthase［J］. Proc Natl Acad Sci USA, 2011, 108(34): E542-549.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments